BIBF-1120 (Ofev (approved for idiopathic pulmonary fibrosis))
Other Medications · Approved since 2014
Description
BIBF-1120, also known as nintedanib, is a triple angiokinase inhibitor that targets multiple receptor tyrosine kinases involved in angiogenesis and tumor growth. In colorectal cancer, it has been evaluated as an anti-angiogenic therapy, particularly in comparison to bevacizumab for metastatic disease. The drug was tested in combination with standard chemotherapy regimens like mFOLFOX6 for patients with advanced, chemotherapy-refractory colorectal cancer.
Mechanism of Action
BIBF-1120 simultaneously inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-? and - ), and fibroblast growth factor receptors (FGFR-1, -2, -3). By blocking these multiple angiogenic pathways, it disrupts tumor blood vessel formation and maintenance, potentially leading to tumor growth inhibition and improved treatment outcomes.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Ofev (approved for idiopathic pulmonary fibrosis) |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Administration | Oral |
| Year Approved | 2014 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.